Abstract
Background
In advanced gastric cancer few data are available on the efficacy or safety of new drug combination regimens after progression following first-line chemotherapy.
Methods
Patients with histologically confirmed advanced gastric cancer and Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than 2, progressing after first-line chemotherapy, were eligible. Patients were treated with docetaxel 75 mg/m2 on day 1 and oxaliplatin 80 mg/m2 on day 2, every 3 weeks, until progression or unacceptable toxicity.
Results
Between May 2002 and April 2005, 38 patients were enrolled. Men accounted for 73.7% of the patients and the median age was 59 years. The primary tumor was not resected in 47.4% of the patients; the peritoneum was the most frequent metastatic site (60.5%). The first-line treatment was cisplatin, epirubicin, and infusional 5-fluorouracil (ECF) in 81.5% of the patients and cisplatin and infusional 5-fluorouracil (CF) in 15.7%. The median number of cycles was 4.3. The treatment was well tolerated, with no toxic deaths. National Cancer Institute (NCI) grade III-IV neutropenia was frequent (26.3%), but no febrile neutropenia was reported. Severe asthenia (15.7%) and severe nausea (15.7%) required dose reductions in 2 patients and treatment discontinuation in another. The overall response rate was 10.5%, and 18 patients (47.3%) experienced disease stabilization (7 of them with significant clinical benefit). Median time to progression was 4.0 months (range, 2–8 months) and median overall survival was 8.1 months (range, 3–26 months). Thirteen patients (34.2%) also received third-line chemotherapy, with an irinotecan-containing regimen, and their median overall survival was higher than that of the other patients (16.3 vs 6.0 months)
Conclusion
The combination of oxaliplatin and docetaxel shows only marginal activity as second-line treatment, but it has a good tolerability profile. This suggests that there is room for optimizing the schedule as well as for planning sequential treatments in gastric cancer.
Article PDF
Similar content being viewed by others
References
DM Parkin (2001) ArticleTitleGlobal cancer statistics in the year 2000 Lancet Oncol 2 533–3 Occurrence Handle11905707 Occurrence Handle10.1016/S1470-2045(01)00486-7 Occurrence Handle1:STN:280:DC%2BD387ntlCrtw%3D%3D
JR Kelley JM Duggan (2003) ArticleTitleGastric cancer epidemiology and risk factors J Clin Epidemiol 56 1–9 Occurrence Handle12589864 Occurrence Handle10.1016/S0895-4356(02)00534-6
JS Macdonald (2004) ArticleTitleTreatment of localized gastric cancer Semin Oncol 314 566–73 Occurrence Handle10.1053/j.seminoncol.2004.04.022 Occurrence Handle1:CAS:528:DC%2BD2cXntlOrs7w%3D
JK Hu ZX Chen ZG Zhou B Zhang J Tian JP Chen et al. (2002) ArticleTitleIntravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials World J Gastroenterol 8 1023–8 Occurrence Handle12439918 Occurrence Handle1:CAS:528:DC%2BD38XpvVSgu78%3D
B Glimelius K Ekstrom K Hoffman W Graf PO Sjoden U Haglund et al. (1997) ArticleTitleRandomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163–8 Occurrence Handle9093725 Occurrence Handle10.1023/A:1008243606668 Occurrence Handle1:STN:280:ByiB2cjlvFw%3D
A Murad F Santiago A Petroianu PR Rocha MA Rodriguez M Rausch (1993) ArticleTitleModified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer Cancer 72 37–41 Occurrence Handle8508427 Occurrence Handle10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P Occurrence Handle1:STN:280:ByyB1cvlvFM%3D
S Pyrrhonen T Kuitenen P Nyandoto M Kouri (1995) ArticleTitleRandomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587–91
JA Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten et al. (1991) ArticleTitleSequential high dose methotrexate and fluorouracil combined with doxorubicin — a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827–31 Occurrence Handle2016625 Occurrence Handle1:STN:280:By6B3c3itV0%3D
M Ychou C Astre P Rouanet JM Fabre B Saint-Aubert J Domergue et al. (1996) ArticleTitleA phase II study of fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer Eur J Cancer 32A 1933–7 Occurrence Handle8943677 Occurrence Handle10.1016/0959-8049(96)00147-5 Occurrence Handle1:CAS:528:DyaK2sXjvVWgsQ%3D%3D
P Preusser H Wilke W Achterrath U Fink L Lenaz A Heinicke et al. (1989) ArticleTitlePhase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer J Clin Oncol 7 1310–7 Occurrence Handle2671287 Occurrence Handle1:STN:280:BiaA287ls1I%3D
G Cocconi M Bella S Zironi R Algeri F Di Costanzo V De Lisi et al. (1994) ArticleTitleFluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research J Clin Oncol 12 2687–93 Occurrence Handle7989945 Occurrence Handle1:STN:280:ByqD1c7otFU%3D
D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman et al. (1992) ArticleTitleFAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541–8 Occurrence Handle1548519 Occurrence Handle1:STN:280:By2C1Mzps1U%3D
NK Kim YS Park DS Heo C Suh SY Kim KC Park et al. (1993) ArticleTitleA phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813–8 Occurrence Handle8508349 Occurrence Handle10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5 Occurrence Handle1:STN:280:ByyB1cvkvFQ%3D
S Cascinu R Labianca P Alessandroni M Marcellini RR Silva G Pancera et al. (1997) ArticleTitleIntensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgastrim: a report from the Italian Group for the Study of Digestive Tract Cancer J Clin Oncol 15 3313–39 Occurrence Handle9363860 Occurrence Handle1:CAS:528:DyaK2sXnsVensLs%3D
A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe et al. (1999) ArticleTitleRandomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer J Clin Oncol 80 269–72
JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper et al. (1999) ArticleTitleLong term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269–72 Occurrence Handle10390007 Occurrence Handle10.1038/sj.bjc.6690350 Occurrence Handle1:CAS:528:DyaK1MXjtFyksbo%3D
U vanhoefer T Wagner M Lutz E Van Cutsem B Nordlinger S Rause et al. (2001) ArticleTitleRandomized phase II study of weekly 24 h infusion of high dose 5-FU+/− folinic acid (HD-FU+/-FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC trial 40953 Eur J Cancer 37 IssueIDSuppl 6 S27 Occurrence Handle10.1016/S0959-8049(01)80580-3
C Barone DC Corsi C Pozzo A Cassano T Fontana MR Noviello et al. (1998) ArticleTitleTreatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or cisplatin-based regimen: two parallel randomized phase II studies Cancer 82 1460–7 Occurrence Handle9554521 Occurrence Handle10.1002/(SICI)1097-0142(19980415)82:8<1460::AID-CNCR5>3.0.CO;2-D Occurrence Handle1:CAS:528:DyaK1cXivFahtL4%3D
K Fatatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada et al. (1994) ArticleTitleLate phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group Gan To Kagaku Ryoho 21 1033–8
C Pozzo C Barone J Szanto E Padi C Peschel J Bukki et al. (2004) ArticleTitleIrinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann Oncol 15 1773–81 Occurrence Handle15550582 Occurrence Handle10.1093/annonc/mdh473 Occurrence Handle1:STN:280:DC%2BD2crotVGitw%3D%3D
Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, et al. Randomized phase 3 trial of irinotecan (CPT-11+ 5FU/folinic acid (FA) vs CDDP + 5FU in first-line advanced gastric cancer patients. J Clin Oncol 2005;23(S16):(abstract no. 4403)
AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani et al. (2000) ArticleTitleDocetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and European Institute of Oncology (EIO) Ann Oncol 11 301–6 Occurrence Handle10811496 Occurrence Handle10.1023/A:1008342013224 Occurrence Handle1:STN:280:DC%2BD3c3mvFKgsQ%3D%3D
M Constenla R Garcia-Arroyo I Lorenzo N Carrete B Campos P Palacios (2002) ArticleTitleDocetaxel, 5-fluorouracil and leucovorin as treatment for advanced gastric cancer: results of a phase II study Gastric Cancer 5 142–7 Occurrence Handle12378340 Occurrence Handle10.1007/s101200200025 Occurrence Handle1:CAS:528:DC%2BD38XnvVSgt7w%3D
JA Ajani M Fodor E Van Cutsem S Tjulandin V Moiseyenko F Cabial et al. (2000) ArticleTitleMultinational randomized phase II study of docetaxel (T) and cisplatin (C) with or without 5-flurouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC) Proc Am Soc Clin Oncol 19 247a
Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 2005;23(S16):(abstract no. 4002)
DY Kim JH Kim SH Lee TY Kim DS Heo YJ Bang et al. (2003) ArticleTitlePhase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 383–7 Occurrence Handle12598342 Occurrence Handle10.1093/annonc/mdg106 Occurrence Handle1:STN:280:DC%2BD3s%2Fos1Gmsw%3D%3D
SE Al-Batran A Atmaca S Hegewisch-Becker D Jaeger S Hahnfeld HJ Rummel et al. (2004) ArticleTitlePhase II trial of biweekly infusional fluorouracil, folinic acid and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 22 658–63 Occurrence Handle14966088 Occurrence Handle10.1200/JCO.2004.07.042 Occurrence Handle1:CAS:528:DC%2BD2cXpsVajs7Y%3D
F De Vita M Orditura E Matano R Bianco C Carlomagno S Infusino et al. (2005) ArticleTitleA phase II trial of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first line treatment of advanced gastric cancer patients Br J Cancer 9 1644–9 Occurrence Handle10.1038/sj.bjc.6602573 Occurrence Handle1:CAS:528:DC%2BD2MXjvVantro%3D
C Louvet T Andre JM Tigaud F Gamelin JY Douillard R Brunet et al. (2002) ArticleTitlePhase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543–8 Occurrence Handle12454110 Occurrence Handle10.1200/JCO.2002.02.021 Occurrence Handle1:CAS:528:DC%2BD38XovVeisLw%3D
R Tanaka H Ariyama B Qin Y Takii E Baba K Mitsugi et al. (2005) ArticleTitleIn vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines Cancer Chemother Pharmacol 55 595–601 Occurrence Handle15731917 Occurrence Handle10.1007/s00280-004-0966-z Occurrence Handle1:CAS:528:DC%2BD2MXjslOmt7c%3D
Agelaki S, Kouroussis C, Mavroudis D, Kalbakis K, Souglakos J, Reppa D, et al. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:abstract 443
R Simon PF Thall SS Ellenberg (1994) ArticleTitleNew designs for selection of treatments to be tested in randomized clinical trials Stat Med 13 417–29 Occurrence Handle8023026 Occurrence Handle10.1002/sim.4780130506 Occurrence Handle1:STN:280:ByuB1MvmsFw%3D
C Kunisaki T Imada R Yamada S Hatori H Ono Y Otsuka et al. (2005) ArticleTitlePhase II study of docetaxel plus cisplatin as second-line combined therapy in patients with advanced gastric carcinoma Anticancer Res 25 2973–7 Occurrence Handle16080554 Occurrence Handle1:CAS:528:DC%2BD2MXpt1Wrt7o%3D
SH Park WK Kang HR Lee J Park KE Lee SH Lee et al. (2004) ArticleTitleDocetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Am J Clin Oncol 27 477–80 Occurrence Handle15596914 Occurrence Handle10.1097/01.coc.0000136018.81814.79 Occurrence Handle1:CAS:528:DC%2BD2cXps1altbs%3D
A Polyzos N Tsavaris C Kosmas K Polyzos A Giannopoulos E Felekouras et al. (2006) ArticleTitleSubsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin Anticancer Res 26 3749–53 Occurrence Handle17094396 Occurrence Handle1:CAS:528:DC%2BD28Xht1Gmt73P
C Tourningand T Andrè E Achille G Lledo M Flesh D Mery-Mignard et al. (2004) ArticleTitleFOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 15 229–37
LM Rothenberg LA Amit RH Bigelow JD Berlin JL Marshall RK Ramanathan et al. (2003) ArticleTitleSuperiority of oxaliplatin and flurouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059–69 Occurrence Handle12775730 Occurrence Handle10.1200/JCO.2003.11.126 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqtL4%3D
A Grothey D Sargent RM Goldberg HJ Schmoll (2004) ArticleTitleSurvival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment J Clin Oncol 22 1209–14 Occurrence Handle15051767 Occurrence Handle10.1200/JCO.2004.11.037 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGktLo%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barone, C., Basso, M., Schinzari, G. et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 10, 104–111 (2007). https://doi.org/10.1007/s10120-007-0415-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-007-0415-x